Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the international neuroblastoma risk group project

Hervé J. Brisse, M. Beth McCarville, Claudio Granata, K. Barbara Krug, Sandra L. Wootton-Gorges, Kimio Kanegawa, Francesco Giammarile, Matthias Schmidt, Barry L. Shulkin, Katherine K. Matthay, Valerie J. Lewington, Sabine Sarnacki, Barbara Hero, Michio Kaneko, Wendy B. London, Andrew D J Pearson, Susan L. Cohn, Tom Monclair

Research output: Contribution to journalReview article

178 Citations (Scopus)

Abstract

Neuroblastoma is an enigmatic disease entity; some tumors disappear spontaneously without any therapy, while others progress with a fatal outcome despite the implementation of maximal modern therapy. However, strong prognostic factors can accurately predict whether children have "good"or "bad" disease at diagnosis, and the clinical stage is currently the most significant and clinically relevant prognostic factor. Therefore, for an individual patient, proper staging is of paramount importance for risk assessment and selection of optimal treatment. In 2009, the International Neuroblastoma Risk Group (INRG) Project proposed a new staging system designed for tumor staging before any treatment, including surgery. Compared with the focus of the International Neuroblastoma Staging System, which is currently the most used, the focus has now shifted from surgicopathologic findings to imaging findings. The new INRG Staging System includes two stages of localized disease, which are dependent on whether image-defined risk factors (IDRFs) are or are not present. IDRFs are features detected with imaging at the time of diagnosis. The present consensus report was written by the INRG Imaging Committee to optimize imaging and staging and reduce interobserver variability. The rationales for using imaging methods (ultrasonography, magnetic resonance imaging, computed tomography, and scintigraphy), as well as technical guidelines, are described. Definitions of the terms recommended for assessing IDRFs are provided with examples. It is anticipated that the use of standardized nomenclature will contribute substantially to more uniform staging and thereby facilitate comparisons of clinical trials conducted in different parts of the world.

Original languageEnglish (US)
Pages (from-to)243-257
Number of pages15
JournalRadiology
Volume261
Issue number1
DOIs
StatePublished - Oct 2011

Fingerprint

Neoplasm Staging
Neuroblastoma
Guidelines
Observer Variation
Fatal Outcome
Therapeutics
Terminology
Radionuclide Imaging
Ultrasonography
Tomography
Magnetic Resonance Imaging
Clinical Trials
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Brisse, H. J., McCarville, M. B., Granata, C., Krug, K. B., Wootton-Gorges, S. L., Kanegawa, K., ... Monclair, T. (2011). Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the international neuroblastoma risk group project. Radiology, 261(1), 243-257. https://doi.org/10.1148/radiol.11101352

Guidelines for imaging and staging of neuroblastic tumors : Consensus report from the international neuroblastoma risk group project. / Brisse, Hervé J.; McCarville, M. Beth; Granata, Claudio; Krug, K. Barbara; Wootton-Gorges, Sandra L.; Kanegawa, Kimio; Giammarile, Francesco; Schmidt, Matthias; Shulkin, Barry L.; Matthay, Katherine K.; Lewington, Valerie J.; Sarnacki, Sabine; Hero, Barbara; Kaneko, Michio; London, Wendy B.; Pearson, Andrew D J; Cohn, Susan L.; Monclair, Tom.

In: Radiology, Vol. 261, No. 1, 10.2011, p. 243-257.

Research output: Contribution to journalReview article

Brisse, HJ, McCarville, MB, Granata, C, Krug, KB, Wootton-Gorges, SL, Kanegawa, K, Giammarile, F, Schmidt, M, Shulkin, BL, Matthay, KK, Lewington, VJ, Sarnacki, S, Hero, B, Kaneko, M, London, WB, Pearson, ADJ, Cohn, SL & Monclair, T 2011, 'Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the international neuroblastoma risk group project', Radiology, vol. 261, no. 1, pp. 243-257. https://doi.org/10.1148/radiol.11101352
Brisse, Hervé J. ; McCarville, M. Beth ; Granata, Claudio ; Krug, K. Barbara ; Wootton-Gorges, Sandra L. ; Kanegawa, Kimio ; Giammarile, Francesco ; Schmidt, Matthias ; Shulkin, Barry L. ; Matthay, Katherine K. ; Lewington, Valerie J. ; Sarnacki, Sabine ; Hero, Barbara ; Kaneko, Michio ; London, Wendy B. ; Pearson, Andrew D J ; Cohn, Susan L. ; Monclair, Tom. / Guidelines for imaging and staging of neuroblastic tumors : Consensus report from the international neuroblastoma risk group project. In: Radiology. 2011 ; Vol. 261, No. 1. pp. 243-257.
@article{267630fe383f4156aee17212fd926582,
title = "Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the international neuroblastoma risk group project",
abstract = "Neuroblastoma is an enigmatic disease entity; some tumors disappear spontaneously without any therapy, while others progress with a fatal outcome despite the implementation of maximal modern therapy. However, strong prognostic factors can accurately predict whether children have {"}good{"}or {"}bad{"} disease at diagnosis, and the clinical stage is currently the most significant and clinically relevant prognostic factor. Therefore, for an individual patient, proper staging is of paramount importance for risk assessment and selection of optimal treatment. In 2009, the International Neuroblastoma Risk Group (INRG) Project proposed a new staging system designed for tumor staging before any treatment, including surgery. Compared with the focus of the International Neuroblastoma Staging System, which is currently the most used, the focus has now shifted from surgicopathologic findings to imaging findings. The new INRG Staging System includes two stages of localized disease, which are dependent on whether image-defined risk factors (IDRFs) are or are not present. IDRFs are features detected with imaging at the time of diagnosis. The present consensus report was written by the INRG Imaging Committee to optimize imaging and staging and reduce interobserver variability. The rationales for using imaging methods (ultrasonography, magnetic resonance imaging, computed tomography, and scintigraphy), as well as technical guidelines, are described. Definitions of the terms recommended for assessing IDRFs are provided with examples. It is anticipated that the use of standardized nomenclature will contribute substantially to more uniform staging and thereby facilitate comparisons of clinical trials conducted in different parts of the world.",
author = "Brisse, {Herv{\'e} J.} and McCarville, {M. Beth} and Claudio Granata and Krug, {K. Barbara} and Wootton-Gorges, {Sandra L.} and Kimio Kanegawa and Francesco Giammarile and Matthias Schmidt and Shulkin, {Barry L.} and Matthay, {Katherine K.} and Lewington, {Valerie J.} and Sabine Sarnacki and Barbara Hero and Michio Kaneko and London, {Wendy B.} and Pearson, {Andrew D J} and Cohn, {Susan L.} and Tom Monclair",
year = "2011",
month = "10",
doi = "10.1148/radiol.11101352",
language = "English (US)",
volume = "261",
pages = "243--257",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Guidelines for imaging and staging of neuroblastic tumors

T2 - Consensus report from the international neuroblastoma risk group project

AU - Brisse, Hervé J.

AU - McCarville, M. Beth

AU - Granata, Claudio

AU - Krug, K. Barbara

AU - Wootton-Gorges, Sandra L.

AU - Kanegawa, Kimio

AU - Giammarile, Francesco

AU - Schmidt, Matthias

AU - Shulkin, Barry L.

AU - Matthay, Katherine K.

AU - Lewington, Valerie J.

AU - Sarnacki, Sabine

AU - Hero, Barbara

AU - Kaneko, Michio

AU - London, Wendy B.

AU - Pearson, Andrew D J

AU - Cohn, Susan L.

AU - Monclair, Tom

PY - 2011/10

Y1 - 2011/10

N2 - Neuroblastoma is an enigmatic disease entity; some tumors disappear spontaneously without any therapy, while others progress with a fatal outcome despite the implementation of maximal modern therapy. However, strong prognostic factors can accurately predict whether children have "good"or "bad" disease at diagnosis, and the clinical stage is currently the most significant and clinically relevant prognostic factor. Therefore, for an individual patient, proper staging is of paramount importance for risk assessment and selection of optimal treatment. In 2009, the International Neuroblastoma Risk Group (INRG) Project proposed a new staging system designed for tumor staging before any treatment, including surgery. Compared with the focus of the International Neuroblastoma Staging System, which is currently the most used, the focus has now shifted from surgicopathologic findings to imaging findings. The new INRG Staging System includes two stages of localized disease, which are dependent on whether image-defined risk factors (IDRFs) are or are not present. IDRFs are features detected with imaging at the time of diagnosis. The present consensus report was written by the INRG Imaging Committee to optimize imaging and staging and reduce interobserver variability. The rationales for using imaging methods (ultrasonography, magnetic resonance imaging, computed tomography, and scintigraphy), as well as technical guidelines, are described. Definitions of the terms recommended for assessing IDRFs are provided with examples. It is anticipated that the use of standardized nomenclature will contribute substantially to more uniform staging and thereby facilitate comparisons of clinical trials conducted in different parts of the world.

AB - Neuroblastoma is an enigmatic disease entity; some tumors disappear spontaneously without any therapy, while others progress with a fatal outcome despite the implementation of maximal modern therapy. However, strong prognostic factors can accurately predict whether children have "good"or "bad" disease at diagnosis, and the clinical stage is currently the most significant and clinically relevant prognostic factor. Therefore, for an individual patient, proper staging is of paramount importance for risk assessment and selection of optimal treatment. In 2009, the International Neuroblastoma Risk Group (INRG) Project proposed a new staging system designed for tumor staging before any treatment, including surgery. Compared with the focus of the International Neuroblastoma Staging System, which is currently the most used, the focus has now shifted from surgicopathologic findings to imaging findings. The new INRG Staging System includes two stages of localized disease, which are dependent on whether image-defined risk factors (IDRFs) are or are not present. IDRFs are features detected with imaging at the time of diagnosis. The present consensus report was written by the INRG Imaging Committee to optimize imaging and staging and reduce interobserver variability. The rationales for using imaging methods (ultrasonography, magnetic resonance imaging, computed tomography, and scintigraphy), as well as technical guidelines, are described. Definitions of the terms recommended for assessing IDRFs are provided with examples. It is anticipated that the use of standardized nomenclature will contribute substantially to more uniform staging and thereby facilitate comparisons of clinical trials conducted in different parts of the world.

UR - http://www.scopus.com/inward/record.url?scp=80053070127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053070127&partnerID=8YFLogxK

U2 - 10.1148/radiol.11101352

DO - 10.1148/radiol.11101352

M3 - Review article

C2 - 21586679

AN - SCOPUS:80053070127

VL - 261

SP - 243

EP - 257

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -